News

Enzalutamide Prolongs Prostate Cancer Survival After Chemotherapy Fails

Publish date: August 15, 2012

 

FROM THE NEW ENGLAND JOURNAL OF MEDICINE

Click here to see a 2009 video of Dr. Scher discussing the rationale behind MDV3100 efficacy in advanced prostate cancer.

Pages

Recommended Reading

ASCO Weighs in on PSA Screening Controversy
MDedge Internal Medicine
Surgery Didn't Cut Mortality from PSA-Detected Prostate Cancer
MDedge Internal Medicine
Invasive SCC Rates Doubled in Last 20 Years
MDedge Internal Medicine
Washington Post Blasts Proliferation of ESAs for Anemia
MDedge Internal Medicine
FDA Approves mTOR Inhibitor Everolimus for Breast Cancer
MDedge Internal Medicine
Cultivate 'Distress Tolerance' for Early-Stage Prostate Cancer
MDedge Internal Medicine
HPV DNA Test Predicts Cervical Cancer Risk for 18 Years
MDedge Internal Medicine
Would Advanced Prostate Cancer Triple Without PSA Screening?
MDedge Internal Medicine
Rare Brainstem Glioma Doesn't Stop Former Marine
MDedge Internal Medicine
Labs Find Evidence of Cancer Stem Cells
MDedge Internal Medicine